<DOC>
	<DOC>NCT00067756</DOC>
	<brief_summary>The purpose of this study is to find out whether 4-PBA will increase the level of AAT in persons with AAT deficiency whether or not they have liver disease.</brief_summary>
	<brief_title>4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?</brief_title>
	<detailed_description>The purpose of this study is to determine whether 4-PBA will significantly increase serum Z AAT levels in AAT-deficient individuals with and without evidence of hepatocellular injury and to assess its effects on liver injury.</detailed_description>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Age 1865 Serum A1PI levels &lt;11uM an appropriate genetic phenotype/genotype 5 of 10 subjects must have documented laboratory evidence of liver disease Willingness to withhold Prolastin therapy for 6 weeks prior to screening and throughout the 4PBA dosing period (up to 3 months) Any cause of liver disease other than Alpha1 Antitrypsin deficiency Evidence of advanced liver disease HIV positive Use of systemic steroids, ursodeoxycholic acid (Actigall, Urso), or herbs in the prior 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Pulmonary Disease</keyword>
	<keyword>Liver Disease</keyword>
</DOC>